Search - tctmd.com

Displaying 41 - 60 of 461

Sort: Relevancy | Date

Presentation TCT 2016

Early Feasibility Studies in USA: Progress Report From the FDA

Presenter: Andrew Farb, Aaron V. Kaplan, Carla M Wiese

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing III: International Consortium Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Philip James Devereaux

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing II: ACCESS CV Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Manesh R. Patel

October 31, 2016

Presentation TCT 2016

Opportunities and Risks of Data Sharing I: YODA Proposal

Presenter: C. Michael Gibson, A. Michael Lincoff, Harlan Krumholz

October 31, 2016

Presentation TCT 2016

The Moral Imperative and Potential Benefits of Data Sharing: Journalist Perspective

Presenter: C. Michael Gibson, A. Michael Lincoff, Eric D. Peterson

October 31, 2016

Presentation TCT 2016

Pragmatic Simple Trials and Big Data: Implications for NIH Funding

Presenter: Deepak L. Bhatt, Roxana Mehran, Michael S. Lauer

October 31, 2016

Presentation TCT 2016

Pragmatic Simple Trials and Big Data: Advantages and Caveats

Presenter: Deepak L. Bhatt, Roxana Mehran, Robert A. Harrington

October 31, 2016

Presentation TCT 2016

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

Presenter: Owen Faris, Mitchell W. Krucoff, Michael R Minogue

October 31, 2016

Presentation TCT 2016

Keynote Lecture III. National Evaluation System for Health Technology (NEST): Objectives, Accomplishments and Future Directions

Presenter: Owen Faris, Mitchell W. Krucoff, Gregory Daniel

October 31, 2016

Presentation TCT 2016

Strengths and Limitations of Post-Approval Registries as Vehicles to Track Safety and Inform Device Label Expansion

Presenter: Owen Faris, Mitchell W. Krucoff, David R. Holmes Jr.

October 31, 2016

Presentation TCT 2016

Device Performance in Pre-Approval Studies vs Unrestricted Real-World Use: Lessons Learned and Future Opportunities

Presenter: Owen Faris, Mitchell W. Krucoff

October 31, 2016

News Industry News

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

October 31, 2016

Presentation TCT 2016

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Alan G. Fraser

October 31, 2016

Presentation TCT 2016

Key Note Lecture I. FDA/CDRH State of the Union

Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Jeffrey Shuren

October 31, 2016

Presentation TCT 2016

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

Presenter: Matthew G. Hillebrenner, Gregg W. Stone

October 31, 2016

News Industry News

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

October 31, 2016

News Industry News

Study Indicates That Open Heart Surgery May Be Superior To PCI For Treatment Of Left Main Coronary Artery Disease

October 31, 2016

News Industry News

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

October 31, 2016

News Conference News TCT 2016

Are Full, Formal Guidelines Still Useful in the Rapidly Changing TAVR Field?

Todd Neale

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Advertisement

Early Feasibility Studies in USA: Progress Report From the FDA

Opportunities and Risks of Data Sharing III: International Consortium Proposal

Opportunities and Risks of Data Sharing II: ACCESS CV Proposal

Opportunities and Risks of Data Sharing I: YODA Proposal

The Moral Imperative and Potential Benefits of Data Sharing: Journalist Perspective

Pragmatic Simple Trials and Big Data: Implications for NIH Funding

Pragmatic Simple Trials and Big Data: Advantages and Caveats

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

Keynote Lecture III. National Evaluation System for Health Technology (NEST): Objectives, Accomplishments and Future Directions

Strengths and Limitations of Post-Approval Registries as Vehicles to Track Safety and Inform Device Label Expansion

Device Performance in Pre-Approval Studies vs Unrestricted Real-World Use: Lessons Learned and Future Opportunities

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines

Key Note Lecture I. FDA/CDRH State of the Union

The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

Study Indicates That Open Heart Surgery May Be Superior To PCI For Treatment Of Left Main Coronary Artery Disease

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

Are Full, Formal Guidelines Still Useful in the Rapidly Changing TAVR Field?

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content